NCT05487443尚未招募2 期
An Open, Single-arm Prospective Clinical Study Evaluating the Efficacy of Systemic Venous Gemcitabine-based Chemotherapy Combined With Immunocheckpoint Inhibitors in First-line Treatment of Advanced Biliary Malignancies
First People's Hospital of Hangzhou1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年8月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Progression free survival (PFS)
研究概览
简要总结
To the patient of terminal biliary malignancy tumor, how should the patient's treatment plan choose ? To address this problem, this study intends to analyze systemic venous gemcitabine-based chemotherapy regimen combined with immune checkpoint inhibitors in patients with advanced BTC, to evaluate the long-term efficacy and toxicity of patients, and to search for predictable biomarkers. In order to clarify the advantages and disadvantages of intravenous chemotherapy combined with immunotherapy for patients with advanced biliary malignancy, provide certain basis for clinical work, and then select the most suitable treatment plan for patients according to the different characteristics of individual patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Non-bedridden male or female, aged ≥18 years and ≤80 years. Adopts the surgery of Chinese medical association branch of biliary surgery group released the diagnosis and treatment of the bile duct carcinoma surgery expert consensus on biliary tract tumor diagnosis standard, refer to biliary lining after epithelial malignant tumors, including intrahepatic bile duct carcinoma, liver bile duct carcinoma, distal bile duct carcinoma and portal vein gallbladder, or postoperative pathology biopsy for biliary tumor, Staging was performed according to the Joint Council on Cancer (AJCC) TNM version
- •the ECOG score of 0 to 2 points.
- •the histologic diagnosis of unresectable locally advanced, recurrent and/or metastatic malignant tumor, biliary pathology for adenocarcinoma, untreated or always neoadjuvant therapy/adjuvant therapy over time to relapse time > 6 months.
- •not intentional, liver, brain, kidney and other important organ dysfunction and bleeding tendency; No history of blood diseases; Cardiac insufficiency, chest pain (medically uncontrollable). No myocardial infarction occurred during the 12 months prior to the study.
- •the subjects baseline blood routine and biochemical indexes in accordance with the following standards: 80 g/L or higher hemoglobin; Neutrophil absolute count (ANC) ≥1.5×109/L; Platelet ≥100×109/L; ALT, AST≤2.5 times the normal upper limit; ALP≤2.5 times normal upper limit value; Serum total bilirubin <1.5 times normal upper limit; Serum creatinine <1 times normal upper limit; Serum albumin ≥30g/L.
- •there are measurable evaluation target lesions according to the RECIST criteria.
排除标准
- •Younger than 18 or more than 76 years old (inclusive); Or poor general condition, ECOG score >
- •participated in other clinical trials.
- •a blood coagulation dysfunction or history or severe clinical haematology (activities) heart disease, such as symptomatic coronary heart disease (CHD), New York heart association (NYHA) class II or more severe congestive heart failure or severe arrhythmia, drug intervention or within the past 12 months has a history of myocardial infarction.
- •patients with past history has obvious liver and kidney function is not complete.
- •Pregnancy and lactation women, women of childbearing age in the baseline period pregnancy test positive pregnancy test subjects or not. Menopausal women must be in menopause for at least 12 months before pregnancy is considered impossible.
- •multi-source patients with carcinoma and repetition, or brain or meningeal metastasis. All landowners have uncontrolled seizures, central nervous system disease or a history of mental disorders, t
研究组 & 干预措施
Chemotherapy combined with immunotherapy
Experimental
Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
干预措施: Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors (Drug)
结局指标
主要结局
Progression free survival (PFS)
时间窗: 1 month
次要结局
- Overall survival (OS)(1 month)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract CancerBiliary Tract CancerNCT03796429Shanghai Zhongshan Hospital50
进行中（未招募）
不适用
Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal StentsPancreatic Cancer Non-resectableBile Duct CancerPapillary CarcinomaDuodenal CancerNCT06453590Region Stockholm450
终止
2 期
A Study of FOLFOX6 With Bevacizumab for Biliary System CarcinomaBiliary Tract CancerNCT00881504Georgetown University9
终止
2 期
A Study to Evaluate Abemaciclib in Advanced Biliary Tract CarcinomaBiliary Tract CarcinomaNCT04003896Milton S. Hershey Medical Center4
Unknown
不适用
Precise Treatment in Hepatobiliary Cancers (PTHBC)Liver NeoplasmsBiliary Tract NeoplasmsHepatobiliary NeoplasmsNCT02715089Peking Union Medical College Hospital30